Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Cancer Immunol Res. 2018 May 16;6(7):776–787. doi: 10.1158/2326-6066.CIR-17-0649

Figure 5. CS1-NKG2D biAb induces cytotoxicity against MM cells directly proportional to the expression of CS1 and IFNγ production.

Figure 5

(A) Specific lysis of MM.1S (CS1high), NCI-H929 (CS1int), and RPMI-8226 (CS1low) MM cell lines in the presence of IL2-activated PBMCs at varying doses of CS1-NKG2D biAb or control biAb. Results are from five independent experiments. (B) 3 MM patient PBMCs were cocultured with the allogeneic PBMCs of healthy donors in the presence of biAbs (50 μg/mL). Effector cytolytic activity was assessed after 24 hours. Patient CS1+ tumor cells were identified as CD38brightCD138dim/+. Results of 3 MM patient samples are shown. (C) IFNγ production in coculture supernatants of IL2-activated PBMCs and MM.1S MM cells in the presence of PBS, control biAb, or CS1-NKG2D biAb. Results show the mean±S.E.M. of five independent experiments. ***p<0.001 using Linear mixed model.